- Rituximab
- Ibrutinib
- Ventoclax
- Cladribine
- Lenalidomide
- Pomalidomide
- Carfilzomib
- Bortezomib
- Daratumumab
Waldenstrom Macroglobulinemia (WM) Drugs Sales were valued at USD 163.7 million in 2022 and is poised to grow at a CAGR of 6.7% from 2023 to 2029. Waldenström macroglobulinemia (WM) is a rare type of blood cancer that affects white blood cells. It is characterized by the production of an abnormal protein called IgM, which can cause various symptoms, including fatigue, weakness, bleeding, and swelling. WM is slow-growing cancer; most patients live for several years after diagnosis. However, the disease can eventually become life-threatening. The prevalence of WM is estimated to be about 1 in 100,000 people. The average age of diagnosis is 65 years, and men are slightly more likely to be affected than women. The cause of WM is unknown, but it is thought to be a combination of genetic and environmental factors. There is no cure for WM; currently, there are various treatments available to help control the disease. The most common treatments include chemotherapy and radiation therapy. Other treatments that may be used include stem cell transplantation and targeted therapy. The treatment of WM can be challenging, and there are several side effects that can occur. These side effects can vary depending on the treatment type used. Some common side effects of chemotherapy include fatigue, nausea, vomiting, and hair loss. Radiation therapy can cause side effects such as skin burns, fatigue, and diarrhoea. Stem cell transplantation is a major surgery that carries a risk of complications, such as infection and graft-versus-host disease. The mortality rate for WM is about 50% at ten years. However, the survival rate has improved in recent years due to advances in treatment.
Waldenstrom Macroglobulinemia Treatment Market Key Developments:
- In Jan 2022, BeiGene announced the acceptance of its NDA application in China for Brukinsa for the treatment of waldenstrom’s macroglobulinemia (WM).
Waldenstrom Macroglobulinemia Treatment Market Summary
Study Period
2024-2030
Base Year
2023
CAGR
6.7%
Largest Market
North America
Fastest Growing Market
Asia Pacific
Waldenstrom Macroglobulinemia Treatment Market Dynamics
The increase in the prevalence of white blood cancer worldwide can be viewed as a significant market opportunity for the Waldenstrom Macroglobulinemia Pharmaceuticals Market. Adoption of newer line treatments for the WM and molecules creates lucrative opportunities for pharmaceutical manufacturers. Various clinical trials are undergoing for Waldenstrom Macroglobulinemia that will bring newer drug molecules in the near future. Companies are also conducting combination therapies to treat the Waldenstrom Macroglobulinemia disease condition. In the phase 2 clinical study (NCT05734495), Eli Lilly and Company conducted a combination clinical trial for its Pirtobrutinib (a Noncovalent Bruton Tyrosine Kinase (BTK) inhibitor) and Venetoclax (a BCL2 inhibitor) to treat the Waldenstrom Macroglobulinemia (WM) disease.
North America Got Significant Share
Waldenstrom Macroglobulinemia Treatment Market Regional Analysis
Based on regions, the market share is segmented into North America, Asia-Pacific, Europe, the Middle East, and the African region. The Waldenstrom Macroglobulinemia therapeutics Market in North America holds a significant revenue share in 2022, and in the following years, it is predicted to increase rapidly. It is attributed to the increase in number of cases of non-Hodgkin lymphoma (NHL), that results in increase of patients undergoing treatment. In the Europe region, very few companies have received the approval for the WM disease indication.
Latin America
Europe
Asia Pacific
Middle East
North America
Key Features of the Reports
- The report provides granular level information about the market size, regional market share, historic market (2018 to 2022) and forecast (2023 to 2029)
- The report covers in-detail insights about the competitor’s overview, company share analysis, key market developments, and their key strategies
- The report outlines drivers, restraints, unmet needs, and trends that are currently affecting the market
- The report tracks recent innovations, key developments and startup’s details that are actively working in the market
- The report provides plethora of information about market entry strategies, regulatory framework and reimbursement scenario
- The report analyses the impact of socio-political environment through PESTLE Analysis and competition through Porter’s Five Force Analysis in addition to recent technology advancements and innovations in the market
Waldenstrom Macroglobulinemia Treatment Market Segmentation
By Drugs
By Distribution Channel
- Hospital Pharmacy
- Retail Pharmacy
By Geography
- North America
- Europe
- The Asia Pacific
- Latin America
- MEA
Frequently Asked Questions
The Waldenstrom Macroglobulinemia Treatment Market size was valued at USD 163.7 million in 2022 and is expected to grow at a significant CAGR of 6.7% CAGR from 2023 to 2029.
The leading players in the Waldenstrom Macroglobulinemia Treatment Market are Johnson & Johnson Services, Inc, Shionogi Inc, Kyowa Kirin Co., Ltd, Innate Pharma SA, Bioniz, Eisai Co., Ltd, Minophagen Pharmaceutical Co., LTD, Bayer AG, Novartis AG, Gilead Sciences, Inc, Merck & Co., Inc, STI Pharma, LLC, Amerigen Pharmaceuticals Limited, Pfizer Inc., Takeda Pharmaceutical Company Limited., Abbott, and F. Hoffmann-La Roche Ltd.
Historic years considered for the market study are 2018 through 2022, 2022 is considered as the base year for market estimation and Seven years forecast is presented from 2023 – 2029.
| 1. Executive Summary |
| 2. Global Waldenstrom Macroglobulinemia Treatment Market Introduction |
| 2.1.Global Waldenstrom Macroglobulinemia Treatment Market - Taxonomy |
| 2.2.Global Waldenstrom Macroglobulinemia Treatment Market - Definitions |
| 2.2.1.Drugs |
| 2.2.2.Distribution Channel |
| 2.2.3.Region |
| 3. Global Waldenstrom Macroglobulinemia Treatment Market Dynamics |
| 3.1. Drivers |
| 3.2. Restraints |
| 3.3. Opportunities/Unmet Needs of the Market |
| 3.4. Trends |
| 3.5. Product Landscape |
| 3.6. New Product Launches |
| 3.7. Impact of COVID 19 on Market |
| 4. Global Waldenstrom Macroglobulinemia Treatment Market Analysis, 2018 - 2022 and Forecast 2023 - 2029 |
| 4.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million) |
| 4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) |
| 4.3. Market Opportunity Analysis |
| 5. Global Waldenstrom Macroglobulinemia Treatment Market By Drugs, 2018 - 2022 and Forecast 2023 - 2029 (Sales Value USD Million) |
| 5.1. Rituximab |
| 5.1.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million) |
| 5.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.1.3. Market Opportunity Analysis |
| 5.2. Ibrutinib |
| 5.2.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million) |
| 5.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.2.3. Market Opportunity Analysis |
| 5.3. Ventoclax |
| 5.3.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million) |
| 5.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.3.3. Market Opportunity Analysis |
| 5.4. Cladribine |
| 5.4.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million) |
| 5.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.4.3. Market Opportunity Analysis |
| 5.5. Lenalidomide |
| 5.5.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million) |
| 5.5.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.5.3. Market Opportunity Analysis |
| 5.6. Pomalidomide |
| 5.6.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million) |
| 5.6.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.6.3. Market Opportunity Analysis |
| 5.7. Carfilzomib |
| 5.7.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million) |
| 5.7.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.7.3. Market Opportunity Analysis |
| 5.8. Bortezomib |
| 5.8.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million) |
| 5.8.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.8.3. Market Opportunity Analysis |
| 5.9. Daratumumab |
| 5.9.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million) |
| 5.9.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.9.3. Market Opportunity Analysis |
| 6. Global Waldenstrom Macroglobulinemia Treatment Market By Distribution Channel, 2018 - 2022 and Forecast 2023 - 2029 (Sales Value USD Million) |
| 6.1. Hospital Pharmacy |
| 6.1.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million) |
| 6.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.1.3. Market Opportunity Analysis |
| 6.2. Retail Pharmacy |
| 6.2.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million) |
| 6.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.2.3. Market Opportunity Analysis |
| 7. Global Waldenstrom Macroglobulinemia Treatment Market By Region, 2018 - 2022 and Forecast 2023 - 2029 (Sales Value USD Million) |
| 7.1. North America |
| 7.1.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million) |
| 7.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 7.1.3. Market Opportunity Analysis |
| 7.2. Europe |
| 7.2.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million) |
| 7.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 7.2.3. Market Opportunity Analysis |
| 7.3. Asia Pacific (APAC) |
| 7.3.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million) |
| 7.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 7.3.3. Market Opportunity Analysis |
| 7.4. Middle East and Africa (MEA) |
| 7.4.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million) |
| 7.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 7.4.3. Market Opportunity Analysis |
| 7.5. Latin America |
| 7.5.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million) |
| 7.5.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 7.5.3. Market Opportunity Analysis |
| 8. North America Waldenstrom Macroglobulinemia Treatment Market ,2018 - 2022 and Forecast 2023 - 2029 (Sales Value USD Million) |
| 8.1. Drugs Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 8.1.1.Rituximab |
| 8.1.2.Ibrutinib |
| 8.1.3.Ventoclax |
| 8.1.4.Cladribine |
| 8.1.5.Lenalidomide |
| 8.1.6.Pomalidomide |
| 8.1.7.Carfilzomib |
| 8.1.8.Bortezomib |
| 8.1.9.Daratumumab |
| 8.2. Distribution Channel Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 8.2.1.Hospital Pharmacy |
| 8.2.2.Retail Pharmacy |
| 8.3. Country Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 8.3.1.United States of America (USA) |
| 8.3.2.Canada |
| 9. Europe Waldenstrom Macroglobulinemia Treatment Market ,2018 - 2022 and Forecast 2023 - 2029 (Sales Value USD Million) |
| 9.1. Drugs Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 9.1.1.Rituximab |
| 9.1.2.Ibrutinib |
| 9.1.3.Ventoclax |
| 9.1.4.Cladribine |
| 9.1.5.Lenalidomide |
| 9.1.6.Pomalidomide |
| 9.1.7.Carfilzomib |
| 9.1.8.Bortezomib |
| 9.1.9.Daratumumab |
| 9.2. Distribution Channel Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 9.2.1.Hospital Pharmacy |
| 9.2.2.Retail Pharmacy |
| 9.3. Country Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 9.3.1.Germany |
| 9.3.2.France |
| 9.3.3.Italy |
| 9.3.4.United Kingdom (UK) |
| 9.3.5.Spain |
| 9.3.6.Rest of EU |
| 10. Asia Pacific (APAC) Waldenstrom Macroglobulinemia Treatment Market ,2018 - 2022 and Forecast 2023 - 2029 (Sales Value USD Million) |
| 10.1. Drugs Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 10.1.1.Rituximab |
| 10.1.2.Ibrutinib |
| 10.1.3.Ventoclax |
| 10.1.4.Cladribine |
| 10.1.5.Lenalidomide |
| 10.1.6.Pomalidomide |
| 10.1.7.Carfilzomib |
| 10.1.8.Bortezomib |
| 10.1.9.Daratumumab |
| 10.2. Distribution Channel Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 10.2.1.Hospital Pharmacy |
| 10.2.2.Retail Pharmacy |
| 10.3. Country Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 10.3.1.China |
| 10.3.2.India |
| 10.3.3.Australia and New Zealand (ANZ) |
| 10.3.4.Japan |
| 10.3.5.Rest of APAC |
| 11. Middle East and Africa (MEA) Waldenstrom Macroglobulinemia Treatment Market ,2018 - 2022 and Forecast 2023 - 2029 (Sales Value USD Million) |
| 11.1. Drugs Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 11.1.1.Rituximab |
| 11.1.2.Ibrutinib |
| 11.1.3.Ventoclax |
| 11.1.4.Cladribine |
| 11.1.5.Lenalidomide |
| 11.1.6.Pomalidomide |
| 11.1.7.Carfilzomib |
| 11.1.8.Bortezomib |
| 11.1.9.Daratumumab |
| 11.2. Distribution Channel Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 11.2.1.Hospital Pharmacy |
| 11.2.2.Retail Pharmacy |
| 11.3. Country Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 11.3.1.GCC Countries |
| 11.3.2.South Africa |
| 11.3.3.Rest of MEA |
| 12. Latin America Waldenstrom Macroglobulinemia Treatment Market ,2018 - 2022 and Forecast 2023 - 2029 (Sales Value USD Million) |
| 12.1. Drugs Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 12.1.1.Rituximab |
| 12.1.2.Ibrutinib |
| 12.1.3.Ventoclax |
| 12.1.4.Cladribine |
| 12.1.5.Lenalidomide |
| 12.1.6.Pomalidomide |
| 12.1.7.Carfilzomib |
| 12.1.8.Bortezomib |
| 12.1.9.Daratumumab |
| 12.2. Distribution Channel Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 12.2.1.Hospital Pharmacy |
| 12.2.2.Retail Pharmacy |
| 12.3. Country Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 12.3.1.Brazil |
| 12.3.2.Mexico |
| 12.3.3.Rest of LA |
| 13. Competition Landscape |
| 13.1. Market Player Profiles (Introduction, Brand/Product Sales, Financial Analysis, Product Offerings, Key Developments, Collaborations, M & A, Strategies, and SWOT Analysis) |
| 13.2.1.AbbVie |
| 13.2.2.Genentech |
| 13.2.3.Johnson & Johnson |
| 13.2.4.Novartis |
| 13.2.5.Pfizer |
| 13.2.6.Teva Pharmaceuticals |
| 14. Research Methodology |
| 15. Appendix and Abbreviations |
- AbbVie
- Genentech
- Johnson & Johnson
- Novartis
- Pfizer
- Teva Pharmaceuticals
- Beigene